Adamax Peptide Guide: Research Reference and Reported Protocols

Overview

Adamax is a synthetic peptide in the Semax family, derived from the ACTH(4-7) fragment, and studied in Russian research for cognitive and neurological endpoints. This reference guide collects what the published literature reports, how concentration arithmetic works for a vial, and how to verify that material actually contains what its label claims. It does not describe how to administer Adamax, and Adamax is not approved for human use by any regulator. For concentration and dilution math, see our Adamax calculator →

What Adamax is and where the research comes from

Adamax belongs to a family of short synthetic peptides derived from the ACTH(4-7) sequence — the same structural lineage as Semax. The research literature on this family is concentrated in Russian-language publications, with much of the work spanning the 1980s through the 2000s. The most commonly cited studies used rodent models of stroke, ischaemia, and cognitive impairment.

Two features of this literature are worth stating plainly. First, a substantial portion is not indexed in the major English-language databases, so it is harder to assess independently than research published in journals with wide circulation. Second, the endpoints in animal models — maze performance, infarct volume, memory-retention tasks — do not map directly onto human cognitive outcomes. Both features should shape how much weight any summary of the evidence carries.

What the research literature reports

The table below reproduces amounts as reported in published studies, for reference. Different studies used different routes and preparations, and the figures are not interchangeable across them.

Route studied	Amount reported in studies	Interval studied	Research context
Intranasal	100-300 mcg	daily	Rodent stroke and cognitive models
Subcutaneous (animal studies)	50-100 mcg/kg	daily	Ischaemia and neuroprotection models
In-vitro cell culture	micromolar range	continuous exposure	Neuronal survival and gene-expression work

These are study parameters administered under protocol supervision with monitoring. They are not a regimen to follow, and reproducing a published figure carries no implication that it is appropriate for any particular use.

Reported mechanisms

The mechanisms proposed in the literature are worth distinguishing from demonstrated outcomes:

• BDNF and NGF expression — several in-vitro studies report increased neurotrophic factor expression after exposure
• Neuronal survival in ischaemia models — animal studies report reduced infarct volume in treated groups
• Cognitive-task performance — rodent studies report improvements on specific memory and learning tasks
• Antioxidant activity — reported in cell-culture work on oxidative stress models

Every item in that list is a mechanistic or animal-model finding. None of them is a human clinical endpoint, and the gap between those two categories is where most overstatement of peptide research occurs.

Safety considerations

Safety data for this peptide family comes predominantly from animal studies, which is an important limitation: animal safety data does not identify rare human events, drug interactions, or effects in pregnancy. The studies cited most often report that treated animals tolerated the interventions without gross adverse findings — a statement considerably weaker than "shown to be safe."

Anyone assessing Adamax should note the following honestly: the human safety database is essentially empty, there is no approved product, no regulator has evaluated it, and material sold under this name may not be what the label claims. Those four facts together mean the uncertainty is high and mostly irreducible from the outside.

Verifying what is in a vial

A calculator assumes the label is accurate. Independent verification is a separate step:

• HPLC purity testing — establishes what proportion of the material is the target peptide
• Mass spectrometry — confirms molecular identity; short synthetic peptide analogues are difficult to distinguish by other means
• Batch-matched certificate of analysis — ties the result to the specific lot you hold; a COA for another lot proves nothing about yours
• Amino-acid sequence confirmation — for a Semax-family analogue, confirms which analogue the material actually is

Our vendor pages record which suppliers publish batch-level COAs, and the forum collects community testing results — including failed tests — alongside supplier discussion. In independent testing, mislabelled or entirely absent material is common enough that an unverified label should be treated as a claim rather than a fact.

Handling and storage conventions

Unreconstituted (lyophilised) material is generally stable at ambient temperature for the duration of normal shipping and is typically stored frozen for longer-term stability. Once a diluent is added, the solution is usually refrigerated and used within a defined window, because the reconstituted state is less stable than the powder. These are handling conventions rather than arithmetic — verify them against the supplier's own documentation.

What the research shows, and what it does not

The honest summary of the Adamax literature: there is a body of animal-model work reporting neuroprotective and cognitive findings, most of it published in Russian-language journals with limited independent replication in English-language literature. There is no meaningful human clinical evidence base, no approved product, and no regulatory assessment.

Where we summarise this research, we cite the study type so a reader can separate an in-vitro result from an animal-model result from a clinical one. A mechanistic finding in a cell culture is a long way from an outcome in a person, and summaries that blur the distinction are not useful for assessing anything.

Related Peptides

Frequently Asked Questions

Related Guides